Sally C. Pipes
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
Commentary
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Commentary
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Commentary
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
Commentary
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
Commentary
Doctors and patients have endured enough pay cuts from Medicare
Doctors who treat Medicare beneficiaries are in for leaner times, judging from the program’s recently announced reimbursement update. And it will be those beneficiaries who will pay the price. The proposed changes to Medicare’s “fee schedule” would technically increase doctor reimbursement by 2.5%. But the government is also proposing to ...
Commentary
Cashing In On University Patents Means Giving Up On Our Innovation Future
Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation ...
Commentary
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
Commentary
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Commentary
Republicans Must Stand Their Ground On Enhanced Obamacare Subsidies
A group of Republican lawmakers is trying to preserve one of the worst mistakes of former President Biden’s tenure—the enhanced subsidies for health insurance sold through Obamacare’s exchanges. The subsidies—which were first enacted on an explicitly temporary basis during the pandemic before being renewed in 2022—are set to expire at ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
Doctors and patients have endured enough pay cuts from Medicare
Doctors who treat Medicare beneficiaries are in for leaner times, judging from the program’s recently announced reimbursement update. And it will be those beneficiaries who will pay the price. The proposed changes to Medicare’s “fee schedule” would technically increase doctor reimbursement by 2.5%. But the government is also proposing to ...
Cashing In On University Patents Means Giving Up On Our Innovation Future
Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation ...
America Can’t Tariff Its Way to a Manufacturing Boom
President Trump very recently signed an executive order exempting a range of products from his proposed tariffs, including some pharmaceuticals. One day prior, he issued an order exempting generic pharmaceuticals from Japan from tariffs. It’s encouraging news, to be sure — particularly for American patients. But policies which shield vital ...
The illicit trade in weight-loss drugs deserves a crackdown
The market for illicit weight-loss drugs is booming in plain sight. Law enforcement officials will have no choice but to act soon. In July, telehealth firm Hims & Hers was hit with a securities lawsuit alleging that the company sold unapproved knock-off compounded versions of Wegovy in violation of its ...
Republicans Must Stand Their Ground On Enhanced Obamacare Subsidies
A group of Republican lawmakers is trying to preserve one of the worst mistakes of former President Biden’s tenure—the enhanced subsidies for health insurance sold through Obamacare’s exchanges. The subsidies—which were first enacted on an explicitly temporary basis during the pandemic before being renewed in 2022—are set to expire at ...
